List of Excipients in Branded Drug BIVIGAM

« Back to Dashboard

BIVIGAM Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

BIVIGAM is a 10% intravenous immune globulin product containing human normal immunoglobulin and glycine as the principal formulation stabilizer. Its commercial opportunity is driven less by excipient substitution than by protein-stability optimization, supply reliability, packaging, manufacturing scale, and differentiated delivery formats. Because BIVIGAM is a licensed biologic, its core regulatory and competitive risks differ from those of small-molecule drugs.

What excipients are used in BIVIGAM?

BIVIGAM contains human normal immunoglobulin at 10% concentration, glycine, and water for injection. The formulation also contains sodium chloride associated with the manufacturing and final product composition. The product has no antimicrobial preservative and is supplied as a sterile intravenous solution. The labeled pH is approximately 4.6 to 5.1. [1]

Component	Role in BIVIGAM	Commercial relevance
Human normal immunoglobulin	Active biologic substance	Requires protection from aggregation, fragmentation, oxidation, and loss of antibody activity
Glycine	Stabilizer and tonicity-related excipient	Supports protein stability during storage and handling
Water for injection	Vehicle	Requires sterile, controlled manufacturing
Sodium chloride	Ionic-strength and tonicity contribution	Affects osmolality, infusion tolerability, and protein behavior
Container-closure system	Maintains sterility and product integrity	Creates opportunities in glass, elastomer, extractables, and packaging qualification

The formulation is designed for intravenous administration and is not interchangeable with ordinary injectable solutions. The protein concentration, pH, osmolality, aggregation profile, IgA content, and infusion instructions must remain within approved specifications.

How does glycine support BIVIGAM stability?

Glycine is used in immunoglobulin products because it can help stabilize proteins in solution without introducing the same level of formulation complexity associated with larger excipients or surfactant systems. In BIVIGAM, glycine supports the product’s liquid formulation and contributes to the formulation environment during refrigerated storage.

The commercial value of glycine is not based on exclusivity. Glycine is a low-cost, widely available excipient. Its value lies in:

• Pharmaceutical-grade purity and consistent supply.
• Low bioburden and endotoxin control.
• Compatibility with immunoglobulin activity and aggregate limits.
• Reliable performance across manufacturing lots.
• Qualification across commercial-scale filling and storage conditions.

For BIVIGAM, the principal formulation risks are protein aggregation, visible and subvisible particles, chemical degradation, potency loss, and changes in infusion tolerability. A change in glycine concentration, pH, ionic strength, or protein concentration could require comparability work and potentially a regulatory supplement.

What formulation patents protect BIVIGAM?

BIVIGAM is regulated as a biologic under section 351(a) of the Public Health Service Act. It is not a conventional small-molecule product with an Orange Book patent listing. The FDA’s Purple Book, rather than the Orange Book, is the relevant FDA database for licensed biological products and biosimilar relationships. [2,3]

No commercially material BIVIGAM-specific excipient patent protection is apparent from the public product labeling. Glycine-based immunoglobulin formulations are widely used in the plasma-derived immunoglobulin sector. The stronger protection is likely to arise from manufacturing know-how, plasma sourcing, process controls, release testing, and regulatory approvals rather than from ownership of glycine itself.

Potentially protectable technical areas include:

1. Plasma-pool selection and characterization.
2. Fractionation and purification conditions.
3. Viral inactivation and removal.
4. Chromatography and filtration sequences.
5. Low-aggregate liquid formulation control.
6. Container-closure compatibility.
7. Freeze-thaw and temperature excursion stability.
8. Control of IgA, prekallikrein activator, and other process-related impurities.
9. Scalable aseptic filling.
10. Product-specific analytical methods.

These elements can create practical barriers even where a broad composition-of-matter patent is absent.

When does BIVIGAM lose exclusivity?

BIVIGAM does not have a conventional small-molecule exclusivity schedule. It received FDA approval in 2012 as a biologic for primary humoral immunodeficiency. [1] The relevant exclusivity framework is biologic reference-product exclusivity and potential biosimilar competition under the Biologics Price Competition and Innovation Act.

For biologics approved under the Public Health Service Act, the FDA generally applies a 12-year reference-product exclusivity period, subject to statutory rules and regulatory interpretation. BIVIGAM’s approval date places it beyond the basic 12-year period. That does not mean immediate biosimilar competition. A biosimilar sponsor must complete development, file a 351(k) application, obtain FDA approval, and manage any applicable patent and commercial barriers.

The practical timeline is therefore:

Event	BIVIGAM timing
Original FDA approval	2012
Basic 12-year reference-product exclusivity window	Expired in 2024, subject to statutory calculation
Current competitive focus	Biosimilar development, manufacturing capacity, contracting, and supply reliability
Orange Book status	Not the primary patent database for BIVIGAM
Relevant biologic database	FDA Purple Book

What is the FDA regulatory status of BIVIGAM?

BIVIGAM is FDA-approved for the treatment of primary humoral immunodeficiency disease. It is manufactured from pooled human plasma and administered intravenously. Its approval requires extensive controls over plasma donors, viral safety, purification, potency, sterility, and lot release. [1]

The FDA regulatory profile creates several commercial constraints:

• Each manufacturing site requires regulatory qualification.
• Plasma collection and testing are tightly controlled.
• Changes to formulation or manufacturing may require a prior-approval supplement, comparability package, or other CMC filing.
• The product must maintain validated viral clearance and pathogen-control performance.
• New dosage forms are not simple line extensions.
• A biosimilar applicant must establish high similarity through analytical, pharmacokinetic, clinical, and immunogenicity evidence appropriate to the product.

For excipient suppliers, regulatory documentation is a core selling requirement. A supplier must provide robust change-control procedures, impurity profiles, elemental impurity data where relevant, residual solvent information, microbial controls, and supply-continuity commitments.

What excipient strategies could improve BIVIGAM?

Glycine optimization

The lowest-risk strategy is optimization within the existing glycine-based platform. Development work could examine glycine concentration, pH, ionic strength, and protein concentration to improve:

• Reduced aggregation during prolonged storage.
• Lower particle formation.
• Better stability during temperature excursions.
• Improved infusion tolerability.
• Greater manufacturing yield.
• Longer in-use stability after vial puncture or dilution, where clinically appropriate.

A formulation change would require comparability against the approved product, including potency, purity, aggregate profile, fragmentation, charge variants, and functional antibody activity.

Surfactant or anti-aggregation systems

Surfactants such as polysorbates or poloxamers are common in biologics but are not automatically suitable for plasma-derived immunoglobulin. They can introduce oxidation, peroxide, leachable, and degradation risks. They may also complicate analytical control.

A surfactant strategy could be commercially attractive if it reduces agitation-induced aggregation or improves stability during shipping. The principal barrier is proving that the excipient does not adversely affect product quality, infusion safety, or long-term stability.

Low-IgA and tolerability-focused formulations

A differentiated BIVIGAM formulation could target patients with heightened sensitivity to immunoglobulin products or infusion-related reactions. Lower IgA content, reduced osmolality, altered pH, or a slower-release delivery format could support medical differentiation.

The commercial benefit would depend on clinical evidence and payer acceptance. A lower-IgA claim cannot rely only on excipient selection; it also depends on plasma selection, purification, process control, and validated assay performance.

Higher concentration products

A higher-concentration immunoglobulin product could reduce infusion volume and administration time. The formulation challenge is maintaining acceptable viscosity, stability, osmolality, and infusion tolerability as protein concentration increases.

This strategy could be more commercially meaningful than simple glycine substitution because hospitals and infusion centers value reduced chair time, lower handling burden, and improved throughput. It would require a new product or substantial regulatory change rather than a routine excipient adjustment.

Subcutaneous conversion

Subcutaneous immunoglobulin products use different formulation and administration requirements. They may require higher concentrations, distinct volume limits, local tolerability optimization, and a device or administration system. BIVIGAM’s existing intravenous formulation cannot simply be relabeled for subcutaneous use.

A subcutaneous BIVIGAM line extension could expand home-infusion access and reduce dependence on infusion centers. The opportunity would compete with established subcutaneous immunoglobulin products and would require clinical and device development.

What commercial opportunities exist for excipient suppliers?

Pharmaceutical-grade glycine

Glycine is the most direct opportunity. Suppliers can compete through:

• Dual-region manufacturing.
• Shorter lead times.
• Lot-to-lot consistency.
• Validated low-endotoxin grades.
• Regulatory support.
• Inventory programs for biologics manufacturers.
• Price stability and supply assurance.

Because glycine is a commodity-like material, the supplier must compete on quality systems, continuity, and documentation rather than exclusivity.

Protein-stabilization platforms

Specialty excipient companies could pursue proprietary stabilizer systems for immunoglobulin products. The value proposition would need to show measurable improvement in aggregation, temperature excursion performance, fill-finish yield, or shelf life.

The strongest commercial model would combine an excipient with formulation development, analytical methods, and regulatory support. A stand-alone excipient is easier to replace than a validated formulation platform.

Container-closure systems

BIVIGAM is supplied in vials, creating opportunities in:

• Low-binding glass.
• Elastomeric stoppers with reduced extractables.
• Improved seal integrity.
• Siliconization control.
• Reduced particle generation.
• Tamper-evident secondary packaging.
• Packaging designed for cold-chain transport.

Container-closure changes may offer a lower clinical risk than changing the active formulation, although they still require extractables and leachables evaluation, container-closure integrity testing, and stability studies.

Cold-chain and shipping systems

BIVIGAM’s labeled storage conditions create demand for validated refrigerated logistics, temperature-monitoring systems, and packaging that limits excursions. A logistics provider that can reduce excursion-related product loss may capture value without changing the approved formulation.

How strong is the BIVIGAM patent estate?

BIVIGAM’s practical protection is stronger in manufacturing and regulatory execution than in excipient exclusivity. The product depends on a controlled plasma-derived manufacturing process, validated viral safety, qualified facilities, and consistent lot release.

Protection category	Relative importance for BIVIGAM
Glycine composition patent	Low
Broad product patent	Limited public visibility
Manufacturing process know-how	High
Plasma supply and donor network	High
Viral clearance validation	High
Analytical release methods	High
Regulatory approval history	High
Packaging and cold-chain systems	Moderate
Biosimilar development burden	High
Trade secrets and operational know-how	High

A competitor may be able to avoid a narrow formulation claim while still facing major technical and commercial barriers. Plasma availability, manufacturing scale, clinical comparability, and contracting can matter more than a single patent claim.

Which companies challenge BIVIGAM?

Publicly identified, approved BIVIGAM-specific biosimilar competitors have not established a visible commercial presence comparable to the reference product. The competitive set is broader than direct BIVIGAM biosimilars and includes other intravenous immunoglobulin products such as Privigen, Octagam, Gamunex-C, and Flebogamma, as well as subcutaneous products such as Hizentra, Cutaquig, and Xembify. [4-8]

Competition occurs through:

• Hospital formulary contracts.
• Group purchasing organizations.
• Infusion-center supply agreements.
• Product availability.
• Infusion tolerability.
• Concentration and administration volume.
• Plasma supply reliability.
• Pricing and rebates.

Because immunoglobulin products are not clinically interchangeable solely because they share the same therapeutic class, switching decisions often depend on physician preference, patient history, payer rules, and product availability.

What generic entry risks exist for BIVIGAM?

Traditional generic substitution is not the principal risk. The relevant risk is biosimilar or competing biologic entry.

Biosimilar risk

A biosimilar applicant would need to address:

• Primary amino-acid sequence and immunoglobulin composition.
• Purity and aggregate levels.
• Antibody functionality.
• Glycosylation and other quality attributes.
• Viral safety.
• Immunogenicity.
• Clinical pharmacology.
• Manufacturing consistency.
• Plasma-derived product variability.

The regulatory burden is substantial, but the product’s age and large market make future competition commercially plausible.

Product shortage risk

The more immediate operating risk is supply disruption. Plasma collection constraints, manufacturing interruptions, quality investigations, and cold-chain failures can affect market share quickly. A reliable supplier with redundant manufacturing and plasma access can gain business even without a lower price.

Substitution risk from newer delivery formats

Subcutaneous immunoglobulin and home-infusion models can erode demand for intravenous administration. The risk is greatest in patients who can transition safely to self-administration or scheduled home care.

What patent litigation and settlement issues affect BIVIGAM?

BIVIGAM does not have the same visible Paragraph IV litigation profile as a small-molecule product listed in the Orange Book. A biosimilar challenge would proceed through the biologics patent framework, including the statutory patent-exchange process and potential patent litigation under the BPCIA.

Relevant disputes could concern:

• Manufacturing methods.
• Purification steps.
• Formulation parameters.
• Delivery devices.
• Container-closure systems.
• Method-of-use claims.
• Trade-secret misappropriation.
• Patent rights held by plasma or process technology licensors.

No prominent public BIVIGAM-specific settlement agreement has established a generic or biosimilar launch date. Any future settlement would likely address patent scope, manufacturing rights, interchangeability, launch timing, and supply arrangements rather than a conventional Paragraph IV date.

How does BIVIGAM compare with competing IVIG products?

Product	Manufacturer or marketer	Route	Commercial differentiation
BIVIGAM	ADMA Biologics	Intravenous	10% IVIG for primary humoral immunodeficiency
Privigen	CSL Behring	Intravenous	Established IVIG platform and broad hospital presence
Gamunex-C	Grifols	Intravenous/subcutaneous use depending on indication and formulation	Large commercial footprint and multiple indications
Octagam	Octapharma	Intravenous	Global plasma-derived immunoglobulin platform
Flebogamma DIF	Grifols	Intravenous	Plasma-derived IVIG with established international use
Hizentra	CSL Behring	Subcutaneous	Home administration and subcutaneous delivery
Xembify	Grifols	Subcutaneous	Home-based subcutaneous immunoglobulin option

BIVIGAM’s commercial position depends on product availability, payer access, physician familiarity, infusion performance, and ADMA’s broader plasma-derived portfolio. Excipient differentiation alone is unlikely to displace established products.

Key Takeaways

• BIVIGAM uses a glycine-based liquid immunoglobulin formulation.
• Glycine is commercially important as a qualified, consistent pharmaceutical excipient, not as a source of meaningful exclusivity.
• BIVIGAM is governed by biologic exclusivity and Purple Book considerations, not the conventional Orange Book framework.
• The core reference-product exclusivity period has passed, but biosimilar entry still requires substantial development and regulatory work.
• The strongest commercial barriers are plasma supply, manufacturing know-how, viral safety, analytical control, and regulatory execution.
• Higher concentration, low-IgA positioning, improved temperature stability, container-closure upgrades, and subcutaneous conversion offer the most credible formulation-led opportunities.
• Traditional Paragraph IV litigation and ordinary generic substitution are not the primary BIVIGAM risks.
• Competing IVIG products and subcutaneous immunoglobulins create greater near-term commercial pressure than a simple excipient substitute.

FAQs

Can BIVIGAM be reformulated with a different amino acid?

Yes, but replacing glycine would require extensive comparability, stability, safety, and regulatory work. The commercial benefit must exceed the cost and risk of changing an established biologic formulation.

Is BIVIGAM eligible for automatic generic substitution?

No. BIVIGAM is a biologic, so the relevant pathway is biosimilar approval under section 351(k). Automatic substitution would depend on a separate FDA interchangeability determination and applicable state law.

Could a new BIVIGAM formulation receive patent protection?

Potentially. Patentable subject matter could include a defined formulation range, higher-concentration product, stability profile, container-closure combination, delivery system, or manufacturing process. Patentability would depend on novelty, non-obviousness, enablement, and claim scope.

Does BIVIGAM have an Orange Book patent expiration date?

The Orange Book is not the controlling FDA reference for BIVIGAM because it is a biologic. Patent and regulatory exclusivity analysis should use the Purple Book, FDA biologics records, USPTO data, and applicable BPCIA litigation records.

What is the most attractive commercial opportunity around BIVIGAM?

A qualified supply and formulation platform that improves stability, reduces aggregate formation, supports higher concentration, or enables efficient home administration has greater potential than commodity glycine supply alone.

References

1. U.S. Food and Drug Administration. (2024). BIVIGAM (immune globulin intravenous [human], 10%) prescribing information. ADMA Biologics, Inc.

2. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.

3. U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products.

4. CSL Behring. (2024). Privigen prescribing information.

5. Grifols. (2024). Gamunex-C prescribing information.

6. Octapharma. (2024). Octagam 10% prescribing information.

7. Grifols. (2024). Flebogamma DIF prescribing information.

8. CSL Behring. (2024). Hizentra prescribing information.